0345 222 3550 Mental Health, Surgical & Ophthalmic, Palliative Care & Physical Rehabilitation
  • Home
  • About Us
  • Services
  • Resources
    • Live View
    • e-Works electronic prescribing
    • Health Awareness Resources
    • Clinical Guidelines
    • Choice & Medication
    • MaPPs (Medicines: A Patient Profile Summary)
    • NEWT Guidelines
    • Patient information leaflets
  • Order Online
  • Blog
    • Press Releases
  • Contact Us
    • Careers
    • Frequently Asked Questions
Improving quality and compliance in medicines management Improving quality and compliance in medicines management
  • Home
  • About Us
  • Services
  • Resources
    • Live View
    • e-Works electronic prescribing
    • Health Awareness Resources
    • Clinical Guidelines
    • Choice & Medication
    • MaPPs (Medicines: A Patient Profile Summary)
    • NEWT Guidelines
    • Patient information leaflets
  • Order Online
  • Blog
    • Press Releases
  • Contact Us
    • Careers
    • Frequently Asked Questions

Archives

Monthly Archive for: "July, 2013"
Home /
 Actioning the Pharmacist Audits
0
By Graham Connolly
In Improving Compliance, Medicines Management Processes
Posted 27th July 2013

Actioning the Pharmacist Audits

One of the key roles of the visiting pharmacist is to make sure that medicines are used safely and appropriately. This involves monitoring the prescription charts to ensure legal requirements are [...]

READ MORE
 NEW PRODUCT – Ashtons Controlled Drugs Register
0
By Graham Connolly
In Improving Compliance, Medicines Management Processes, Simplifying Product Supply
Posted 26th July 2013

NEW PRODUCT – Ashtons Controlled Drugs Register

All hospitals and other healthcare settings must have controlled drugs (CD) registers to record their stocks of CDs in order to comply with regulations. There are a variety of controlled drugs [...]

READ MORE
 MHRA Safety Warning regarding Electronic Cigarettes
0
By Graham Connolly
In Clinical Guidelines, MRHA News and Safety Alerts
Posted 24th July 2013

MHRA Safety Warning regarding Electronic Cigarettes

The MHRA proposes to regulate e-cigarettes following their widespread use and the current lack of safety or quality monitoring. The will be licensed as medicines in the same way as [...]

READ MORE
 Clozapine fatality associated with constipation
0
By Graham Connolly
In Mental Health, Pharmacy Information
Posted 23rd July 2013

Clozapine fatality associated with constipation

There has been a report in the national media of a fatality caused by clozapine-induced severe constipation, which occurred to an inpatient at a hospital in the UK. All patients prescribed [...]

READ MORE
 Competency Assessment for Medicines Administration
0
By Graham Connolly
In Medicines Management Processes
Posted 23rd July 2013

Competency Assessment for Medicines Administration

It is a regulatory requirement of the Care Quality Commission’s Essential Standards of Quality and Safety (Outcome 9) that “staff handling medicines have the competency and skills [...]

READ MORE
 NICE Guidance on Social Anxiety Disorder (CG 159)
0
By Graham Connolly
In Clinical Guidelines, NICE guidelines
Posted 21st July 2013

NICE Guidance on Social Anxiety Disorder (CG 159)

Social anxiety disorder (or social phobia) is very common, with an estimated lifetime prevalence of 12%. Co-morbidity with other mental health problems such as depression, substance misuse and [...]

READ MORE
 OBSERVA Study
0
By Graham Connolly
In Improving Compliance, Medicines Management Processes, Mental Health, MRHA News and Safety Alerts
Posted 20th July 2013

OBSERVA Study

Last year, Ashtons was involved in a safety study for the MHRA, which involved monitoring the side effects of different formulations of quetiapine tablets. This year, we have been asked to carry [...]

READ MORE
 NEW DRUG – Nalmefene (Selincro®)
0
By Graham Connolly
In New Product, Pharmacy Information, Simplifying Product Supply
Posted 19th July 2013

NEW DRUG – Nalmefene (Selincro®)

Nalmefene reduces the amount of alcohol that a heavy drinker will consume. Reducing alcohol intake is a positive step towards abstinence, and nalmefene should be used in conjunction with [...]

READ MORE
 NEW DRUG – Lisdexamfetamine (Elvanse®)
0
By Graham Connolly
In Mental Health, New Product, Pharmacy Information, Simplifying Product Supply
Posted 18th July 2013

NEW DRUG – Lisdexamfetamine (Elvanse®)

July 2013 – Lisdexamfetamine is indicated for ADHD (attention deficit/hyperactivity disorder) in children over 6 years, where clinical response to methylphenidate has been inadequate. [...]

READ MORE
Subscribe to Ashtons Pharmacy News

Follow us
Accreditations




What is this?

Resources
Online ordering
Ashtons Live View
MaPPs
Choice and medication
NEWT guidelines
Ashtons
Contact Us
Careers
FAQs
Terms & Conditions
Statutory Licences
Privacy Policy
Cookie Policy
COVID-19 Risk Assessment

Start typing and press Enter to search